Orexigen Therapeutics (OREX) Misses Q4 EPS by 4c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. SPCX
2. NVDA
3. NFLX
4. META
5. TSLA
6. ISRG
7. SMCI
8. GOOGL
9. RTX
10. S

Go back to Orexigen Therapeutics (OREX) Misses Q4 EPS by 4c

Piper Jaffray Cuts Price Target on Orexigen Therapeutics (OREX) to $5 Following 4Q Results

February 29, 2016 8:13 AM EST

Piper Jaffray maintained an Overweight rating on Orexigen Therapeutics (NASDAQ: OREX), and cut the price target to $5.00 (from $11.00), following the company's 4Q earnings report. US Contrave royalties of $2.6M, helped OREX end 2015 with $214M of cash, sufficient through profitability based on growing revenues. Orexigen reported 4Q15 revenues of $4.9M, including $2.6M in Contrave... More

UPDATE: RBC Capital Downgrades Orexigen Therapeutics (OREX) to Sector Perform

February 29, 2016 6:52 AM EST

(Updated - February 29, 2016 8:24 AM EST)

RBC Capital downgraded Orexigen Therapeutics (NASDAQ: OREX) from Outperform to Sector Perform with a price target of $1.00 (from $5.00). Analyst Simos Simeonidis sees a tougher road for Contrave/ Mysimba.

"Despite the already significant decline in OREX shares, we are downgrading to Sector Perform on what we view as a bleak outlook for both the US... More